Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:613-617
Published online before print January 5, 2004, doi: 10.1161/01.ATV.0000116026.18945.66
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
24/3/613    most recent
01.ATV.0000116026.18945.66v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Keuren, J. F.W.
Right arrow Articles by Lindhout, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keuren, J. F.W.
Right arrow Articles by Lindhout, T.
Related Collections
Right arrow Coagulation
Right arrow Thrombin
Right arrow Coagulation inhibitors
Right arrow Heparin
Right arrow Platelets
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:613.)
© 2004 American Heart Association, Inc.


Thrombosis

Covalently-Bound Heparin Makes Collagen Thromboresistant

Jeffrey F.W. Keuren; Simone J.H. Wielders; Anita Driessen; Michel Verhoeven; Marc Hendriks; Theo Lindhout

From the Department of Biochemistry (J.F.W.K., T.L.) and the Cardiovascular Research Institute (S.J.H.W., T.L.), Maastricht University, 6200 MD Maastricht, The Netherlands; and the Medtronic Bakken Research Center B.V. (A.D., M.V., M.H.), 6229 GW Maastricht, The Netherlands.

Correspondence to Dr. T. Lindhout, Department of Biochemistry, Maastricht University, PO Box 616, 6200 MD Maastricht, The Netherlands. E-mail t.lindhout{at}bioch.unimaas.nl

Objective— Blood compatibility of artificial surfaces depends on their immunogenic and thrombogenic properties. Collagen’s weak antigenicity makes it an attractive candidate for stent coatings or fabrication of vascular grafts. However, the thrombogenic nature of collagen limits its application. We examined whether heparinization can make collagen more thromboresistant.

Methods and Results— Collagen was heparinized by crosslinking collagen with extensively periodate oxidized heparin and/or by covalently bonding of mildly periodate oxidized heparin. Both ways of heparinization have no effect on platelet adhesion and could not abolish induction of platelet procoagulant activity. However, thrombin generation was completely prevented under static and flow conditions. The functionality of immobilized heparin was confirmed by specific uptake of antithrombin, 13.5±4.7 pmol/cm2 and 1.95±0.21 pmol/cm2 for mildly and heavily periodated heparin, respectively.

Conclusions— These results indicate that immobilization of heparin on collagen, even as a crosslinker, is a very effective way to prevent surface thrombus formation. These data encourage the application of heparinized collagen as stent-graft material in animal and eventually human studies.


Key Words: collagen • heparin • thrombogenicity • thrombosis • blood flow




This article has been cited by other articles:


Home page
VASC ENDOVASCULAR SURGHome page
D. R. Whittaker and M. F. Fillinger
The Engineering of Endovascular Stent Technology: A Review
Vascular and Endovascular Surgery, March 1, 2006; 40(2): 85 - 94.
[Abstract] [PDF]